As Taltz growth stalls, Lilly looks ahead to psoriatic arthritis expansion
admin 13th October 2017 Uncategorised 0Eli Lilly is counting on psoriasis med Taltz to drive U.S. volume growth. But lately, that growth has stalled. New prescriptions for the next-gen med have stayed relatively flat over the last couple of months, Evercore ISI analyst Umer Raffat pointed out in a Friday note to clients. And new-to-brand prescriptions have actually declined.
More: As Taltz growth stalls, Lilly looks ahead to psoriatic arthritis expansion
Source: fierce